Candel Therapeutics, Inc.
CADLNasdaq
$10.18
↑ +7.4%Jul 17 close · end-of-day
Price
1Y↑ +48.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$634.8M
Enterprise Value
$440.0M
P/E
—
P/S
—
P/B
4.6
EV/EBITDA
—
PEG
—
FCF Yield
-7.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$54.4M
Free Cash Flow (TTM)
-$49.0M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-39.4%
ROIC
—
Debt / Equity
—
Net Cash
$194.8M
Return 1Y
+47.1%
Company profile
Candel Therapeutics, Inc. engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer. CAN-3110, in Phase I clinical trials for the. treatment of recurrent glioblastoma, has completed Phase Ib/II clinical trials.
- CEO
- Paul-Peter Tak
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- Massachusetts
- Website
- candeltx.com
Management & directors
- Barone FrancescaChief Scientific Officer
- Tyagarajan SeshuChief Technology Officer
- Nichols GarrettChief Medical Officer
- Schoch CharlesChief Financial Officer
- Tak Paul PeterChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
CADL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.14↓ -207.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $125,000.00 | $125,000.00 | $125,000.00 | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$13.8M | -$25.7M | -$34.7M | -$38.4M | -$33.4M | -$48.3M |
| Net income | -$17.7M | -$36.1M | -$18.8M | -$37.9M | -$55.2M | -$38.2M |
| Diluted EPS | — | -$1.91 | -$0.65 | -$1.31 | -$1.74 | -$0.72 |
| Operating cash flow | -$9.1M | -$22.2M | -$31.4M | -$34.2M | -$27.0M | -$38.3M |
| Free cash flow | -$10.5M | -$24.1M | -$32.7M | -$34.7M | -$27.0M | -$38.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -11048.0% | -20580.8% | -27777.6% | — | — | — |
| Net margin | -14144.0% | -28899.2% | -15035.2% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.6M | -$8.8M | -$8.1M | -$8.1M | -$11.2M | -$13.2M | -$15.8M | -$16.3M |
| Net income | -$22.2M | -$10.6M | -$14.1M | $7.4M | -$4.8M | -$11.3M | -$29.5M | -$8.9M |
| Diluted EPS | -$0.74 | -$0.33 | -$0.39 | $0.13 | -$0.09 | -$0.21 | -$0.55 | -$0.14 |
| Operating cash flow | -$6.2M | -$6.6M | -$5.8M | -$8.6M | -$8.9M | -$10.2M | -$10.6M | -$18.0M |
| Free cash flow | -$6.2M | -$6.6M | -$5.8M | -$8.6M | -$8.9M | -$10.4M | -$11.0M | -$18.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 30, 2026
- 20d agoCADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’stocktwits.com
- 20d agoCandel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitorsfinance.yahoo.com
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-29 | Barone Francesca· Chief Scientific Officer | Sale | 23,447 | $10.06 | $235,768.96 | filing |
| 2026-06-29 | Tyagarajan Seshu· Chief Technology Officer | Sale | 7,000 | $10.02 | $70,151.20 | filing |
| 2026-02-23 | Manning Paul B | Buy | 550,458 | $5.45 | $3.0M | filing |
| 2025-07-28 | Nichols Garrett· Chief Medical Officer | Sale | 937 | $6.98 | $6,540.26 | filing |
| 2025-07-28 | Nichols Garrett· Chief Medical Officer | Option exercise | 937 | $1.29 | $1,208.73 | filing |
| 2025-06-30 | Nichols Garrett· Chief Medical Officer | Sale | 781 | $5.04 | $3,936.24 | filing |
| 2025-06-30 | Nichols Garrett· Chief Medical Officer | Option exercise | 781 | $1.29 | $1,007.49 | filing |
| 2025-06-25 | Manning Paul B | Award | 1,070,663 | $4.67 | $5.0M | filing |
| 2025-06-25 | Martell Christopher | Award | 111,349 | $4.67 | $519,999.83 | filing |
| 2025-06-25 | PAPA JOSEPH C | Award | 64,239 | $4.67 | $299,996.13 | filing |
| 2025-06-25 | Tak Paul Peter· Chief Executive Officer | Award | 42,826 | $4.67 | $199,997.42 | filing |
| 2025-06-25 | Schoch Charles· Chief Financial Officer | Award | 5,353 | $4.67 | $24,998.51 | filing |
| 2025-06-25 | Nabel Gary J. | Award | 5,353 | $4.67 | $24,998.51 | filing |
| 2025-06-25 | Tyagarajan Seshu· Chief Technology Officer | Award | 5,353 | $4.67 | $24,998.51 | filing |
| 2025-06-25 | Barone Francesca· Chief Scientific Officer | Award | 4,282 | $4.67 | $19,996.94 | filing |
| 2025-06-25 | Loggia Nicoletta | Award | 2,141 | $4.67 | $9,998.47 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.